Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ENSARTINIB HYDROCHLORIDE
- A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions
- Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
- A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
- Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
- Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance
- Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
- X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
- The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
- X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
- Phase II Umbrella Study Directed by Next Generation Sequencing
- Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers
- A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
- Treating Patients With Melanoma and ALK Alterations With Ensartinib
- X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
- Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Clinical trials list
click for details